Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai's anticancer agent Treakisym (bendamustine hydrochloride) has got marketing approval in Japan for the treatment of relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma.
Subscribe to our email newsletter
Treakisym is an anticancer agent that exhibits both nitrogen mustard-derived alkylating activity and antimetabolic-like activity.
Treakisym is the subject of a licensing agreement concluded between Eisai and SymBio Pharmaceuticals, under which SymBio is responsible for developing and obtaining marketing approval for the drug in Japan, while Eisai will market it exclusively.
In the clinical studies Treakisym demonstrated efficacy, with a high response rate, and extended the duration of progression-free survival, Eisai said.